Provided by Tiger Trade Technology Pte. Ltd.

Biogen

216.78
+2.431.13%
Post-market: 216.780.00000.00%19:30 EDT
Volume:722.35K
Turnover:156.95M
Market Cap:32.00B
PE:38.50
High:219.12
Open:217.76
Low:215.00
Close:214.35
52wk High:222.15
52wk Low:131.52
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.01
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.70
PE(LYR):24.66

Loading ...

Eisai Limited: Cda-amc Recognizes Clinical Value of Leqembi & Recommends Public Coverage for Early Alzheimer's Disease

THOMSON REUTERS
·
Jul 16

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 16

Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO

Stock News
·
Jul 15

Biogen Names Michael Parini Chief Legal Officer Effective Aug. 3

Reuters
·
Jul 15

Biogen Appoints Michael J. Parini as Chief Legal Officer

THOMSON REUTERS
·
Jul 15

Biogen: CELIA Phase 2 Data Underpin Continued Confidence in Diranersen; Buy Rating and $256 Price Target Reiterated

TIPRANKS
·
Jul 15

Biogen Inc. Stock Slips 8.2%, Underperforms Peers

Dow Jones
·
Jul 15

IBM, Goldman Sachs, SK Hynix, Micron, Crowdstrike, Biogen, and More Stocks That Explain Today's Market

Dow Jones
·
Jul 15

Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206

MT Newswires Live
·
Jul 15

Biogen Stock Sinks on Lackluster Alzheimer's News

Dow Jones
·
Jul 14

RBC says Biogen detailed Phase 2 results ‘leave more questions than answers’

TIPRANKS
·
Jul 14

Biogen to face questions on safety and dose response, says Stifel

TIPRANKS
·
Jul 14

Eisai, Biogen announce presentation of results from real-world LEADER study

TIPRANKS
·
Jul 14

Leqembi® Real-world Leader Study Presented at Aaic® 2026 Finds over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved over an Average of 17 Months of Treatment

THOMSON REUTERS
·
Jul 14

Movement Alert|Biogen Falls 7.06% in Regular Trading, Diranersen Phase 2 CELIA Full Data Reveals Missed Primary Endpoint Sparking Registration Path Concerns

Market Focus
·
Jul 14

Biogen Down over 7%, on Pace for Largest Percent Decrease Since November 2020

Dow Jones
·
Jul 14

Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)

TIPRANKS
·
Jul 14

Biogen Shares Down 6.2% After Co's Experimental Alzheimer's Drug Misses Main Goal in Mid-stage Study

THOMSON REUTERS
·
Jul 14

Biogen announces expanded data from CELIA study evaluating diranersen

TIPRANKS
·
Jul 14

Biogen Plans Phase 3 Development of Alzheimer’s Tau Therapy Diranersen After Phase 2 Data

Reuters
·
Jul 14